Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96


Aerosol administration of phospho-sulindac inhibits lung tumorigenesis.

Cheng KW, Wong CC, Alston N, Mackenzie GG, Huang L, Ouyang N, Xie G, Wiedmann T, Rigas B.

Mol Cancer Ther. 2013 Aug;12(8):1417-28. doi: 10.1158/1535-7163.MCT-13-0006-T. Epub 2013 May 3.


Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles.

Zhu R, Cheng KW, Mackenzie G, Huang L, Sun Y, Xie G, Vrankova K, Constantinides PP, Rigas B.

Pharm Res. 2012 Nov;29(11):3090-101. doi: 10.1007/s11095-012-0801-x. Epub 2012 Jun 22.


Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.

Bao R, Lai CJ, Wang DG, Qu H, Yin L, Zifcak B, Tao X, Wang J, Atoyan R, Samson M, Forrester J, Xu GX, DellaRocca S, Borek M, Zhai HX, Cai X, Qian C.

Mol Cancer Ther. 2009 Dec;8(12):3296-306. doi: 10.1158/1535-7163.MCT-09-0538.


In vitro and in vivo antitumor activity of a novel semisynthetic derivative of cucurbitacin B.

Silva IT, Carvalho A, Lang KL, Dudek SE, Masemann D, Durán FJ, Caro MS, Rapp UR, Wixler V, Schenkel EP, Simões CM, Ludwig S.

PLoS One. 2015 Feb 12;10(2):e0117794. doi: 10.1371/journal.pone.0117794. eCollection 2015.


Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways.

Pal HC, Sharma S, Strickland LR, Agarwal J, Athar M, Elmets CA, Afaq F.

PLoS One. 2013 Oct 4;8(10):e77270. doi: 10.1371/journal.pone.0077270. eCollection 2013.


Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.

Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA.

PLoS One. 2010 Nov 29;5(11):e14124. doi: 10.1371/journal.pone.0014124.


Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics.

Cheng KW, Wong CC, Mattheolabakis G, Xie G, Huang L, Rigas B.

Int J Oncol. 2013 Sep;43(3):895-902. doi: 10.3892/ijo.2013.1995. Epub 2013 Jun 27.


Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.

Chen J, Bi H, Hou J, Zhang X, Zhang C, Yue L, Wen X, Liu D, Shi H, Yuan J, Liu J, Liu B.

Cell Death Dis. 2013 Sep 26;4:e814. doi: 10.1038/cddis.2013.312.


A novel sulindac derivative inhibits lung adenocarcinoma cell growth through suppression of Akt/mTOR signaling and induction of autophagy.

Gurpinar E, Grizzle WE, Shacka JJ, Mader BJ, Li N, Piazza NA, Russo S, Keeton AB, Piazza GA.

Mol Cancer Ther. 2013 May;12(5):663-74. doi: 10.1158/1535-7163.MCT-12-0785. Epub 2013 Feb 26.


NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling.

Zhou H, Liu W, Su Y, Wei Z, Liu J, Kolluri SK, Wu H, Cao Y, Chen J, Wu Y, Yan T, Cao X, Gao W, Molotkov A, Jiang F, Li WG, Lin B, Zhang HP, Yu J, Luo SP, Zeng JZ, Duester G, Huang PQ, Zhang XK.

Cancer Cell. 2010 Jun 15;17(6):560-73. doi: 10.1016/j.ccr.2010.04.023.


Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.

Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, Su B, Zhou C.

Adv Med Sci. 2011;56(2):275-84. doi: 10.2478/v10039-011-0043-x.


Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.

Freeman DJ, Bush T, Ogbagabriel S, Belmontes B, Juan T, Plewa C, Van G, Johnson C, Radinsky R.

Mol Cancer Ther. 2009 Jun;8(6):1536-46. doi: 10.1158/1535-7163.MCT-08-0978. Epub 2009 Jun 9.


NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways.

Yu P, Ye L, Wang H, Du G, Zhang J, Zhang J, Tian J.

Tumour Biol. 2015 Mar;36(3):2143-53. doi: 10.1007/s13277-014-2824-x. Epub 2014 Nov 15.


Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.

Lee JY, Lee YM, Chang GC, Yu SL, Hsieh WY, Chen JJ, Chen HW, Yang PC.

PLoS One. 2011;6(8):e23756. doi: 10.1371/journal.pone.0023756. Epub 2011 Aug 17.


ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.

Kang HN, Kim SH, Yun MR, Kim HR, Lim SM, Kim MS, Hong KW, Kim SM, Kim H, Pyo KH, Park HJ, Han JY, Youn HA, Chang KH, Cho BC.

Lung Cancer. 2016 May;95:57-64. doi: 10.1016/j.lungcan.2016.02.013. Epub 2016 Feb 27.


AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).

Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, Goh BC, Smith PD, Soo KC.

J Hepatol. 2010 Jan;52(1):79-87. doi: 10.1016/j.jhep.2009.10.008. Epub 2009 Oct 28.


Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer.

Cheng KW, Mattheolabakis G, Wong CC, Ouyang N, Huang L, Constantinides PP, Rigas B.

Int J Oncol. 2012 Oct;41(4):1199-203. doi: 10.3892/ijo.2012.1577. Epub 2012 Jul 27.


A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells.

Xiong F, Jiang M, Huang Z, Chen M, Chen K, Zhou J, Yin L, Tang Y, Wang M, Ye L, Zhan Z, Duan J, Fu H, Zhang X.

Integr Cancer Ther. 2014 Mar;13(2):152-60. doi: 10.1177/1534735413503544. Epub 2013 Oct 7.


Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.

Sano Y, Hashimoto E, Nakatani N, Abe M, Satoh Y, Sakata K, Fujii T, Fujimoto-Ouchi K, Sugimoto M, Nagahashi S, Aoki M, Motegi H, Sasaki E, Yatabe Y.

Mol Cancer Ther. 2015 Feb;14(2):533-41. doi: 10.1158/1535-7163.MCT-14-0456. Epub 2014 Dec 18.

Supplemental Content

Support Center